FOLOTYN: FDA Approved Drugs and User Comments
' + "
";
evCat = 'adx-impl';
evLabel = '/21865806531/yl-xk/336*280-01-wap-xk-yl';
} else {
html = "
" + '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/728*90-01-pc-xk-yl", [728, 90], "div-gpt-ad-1576640512222-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576640512222-0")});
' + "
";
evCat = 'adx-impl';
evLabel = '/21865806531/yl-xk/728*90-01-pc-xk-yl';
}
var html2 = replaceAll2(html, "script2", "script");
fillHtml += randomAdxSlotId(html2);
_pf_event(evCat, PAGE_CAT, evLabel);
_pf_log("ga adsense single");
}
document.write(fillHtml);
}
showAd();
})();
Drug Name |
Active Ingredients |
Strength |
Dosage Form/Route |
Marketing Status |
FOLOTYN |
PRALATREXATE |
20MG/ML (20MG/ML) |
SOLUTION;INTRAVENOUS |
Prescription |
FOLOTYN |
PRALATREXATE |
40MG/2ML (20MG/ML) |
SOLUTION;INTRAVENOUS |
Prescription |
* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
";
}
function showAd(){
var s = getQueryStringByName('s');
var isSearchPage = (s != '');
var isMobile = /iPhone|iPad|iPod|Android/i.test(navigator.userAgent);
var html = '';
var html2 = '';
if (isSearchPage) {
if (isMobile) {
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/336x280-01-wap-n-xk-yl", [336, 280], "div-gpt-ad-1576640284306-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576640284306-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/336x280-01-wap-n-xk-yl');
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/336x280-02-wap-n-xk-yl", [336, 280], "div-gpt-ad-1576640310637-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576640310637-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/336x280-02-wap-n-xk-yl');
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/336x280-03-wap-n-xk-yl", [336, 280], "div-gpt-ad-1576640337768-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576640337768-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/336x280-03-wap-n-xk-yl');
} else {
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/300x600-01-pc-n-xk-yl", [300, 600], "div-gpt-ad-1576640117816-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576640117816-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/300x600-01-pc-n-xk-yl');
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/300x600-02-pc-n-xk-yl", [300, 600], "div-gpt-ad-1576640172416-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576640172416-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/300x600-02-pc-n-xk-yl');
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/300x600-01-healthtopquestions-xk-yl", [300, 600], "div-gpt-ad-1576639775063-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576639775063-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/300x600-01-healthtopquestions-xk-yl');
}
} else {
if (isMobile) {
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/336x280-04-wap-n-xk-yl", [336, 280], "div-gpt-ad-1576640363074-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576640363074-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/336x280-04-wap-n-xk-yl');
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/336x280-05-wap-n-xk-yl", [336, 280], "div-gpt-ad-1576640388002-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576640388002-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/336x280-05-wap-n-xk-yl');
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/336x280-06-wap-n-xk-yl", [336, 280], "div-gpt-ad-1576640412938-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576640412938-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/336x280-06-wap-n-xk-yl');
} else {
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/300x600-01-healthtopquestions-xk-yl", [300, 600], "div-gpt-ad-1576639775063-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576639775063-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/300x600-01-healthtopquestions-xk-yl');
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/300x250-01-healthtopquestions-xk-yl", [300, 250], "div-gpt-ad-1576639270555-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576639270555-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/300x250-01-healthtopquestions-xk-yl');
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/300x600-01-healthtopquestions-xk-yl", [300, 600], "div-gpt-ad-1576639775063-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576639775063-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/300x600-01-healthtopquestions-xk-yl');
}
}
var html2 = replaceAll2(html, 'script2', 'script');
document.write(html2);
}
showAd();
})();
User Comments:
For Peripheral T-cell Lymphoma “My wife had two weekly treatments and developed a high fever, low blood counts, weakness, and confusion and was unable to continue. 15 days in the hospital to come back to previous condition. As there were other issues involved Folotyn was not determined to be the sole cause of her problems. We waited 9 weeks and tried another treatment of Folotyn, one week later we were back in the hospital for 12 days. This has not been a viable treatment for her as it has also had no effect on her PTCL NOS. We will most likely be trying Istodax next.”
ptim (taken for 1 to 6 months) February 10, 2016